Opinion|Videos|February 10, 2025
Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems
Author(s)Debra Fromer, MD
An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram-negative Enterobacterales,” including its objective, design, methodology, results, and key takeaways, and discusses how this data impacts the treatment of inpatient uncomplicated UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly describe the study “Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-spectrum β-lactamase-phenotype Gram-negative Enterobacterales.”
- What was the objective of this study?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. How does this data impact how you treat inpatient UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues
2
New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment
3
Female Newborns More Likely to Miss Vitamin K Prophylaxis, Hepatitis B Birth Dose
4
JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain
5